These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18301059)

  • 1. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
    Weiser B; Philpott S; Klimkait T; Burger H; Kitchen C; Bürgisser P; Gorgievski M; Perrin L; Piffaretti JC; Ledergerber B;
    AIDS; 2008 Feb; 22(4):469-79. PubMed ID: 18301059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
    Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.
    Brumme ZL; Goodrich J; Mayer HB; Brumme CJ; Henrick BM; Wynhoven B; Asselin JJ; Cheung PK; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2005 Aug; 192(3):466-74. PubMed ID: 15995960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
    Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
    AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.
    Moyle GJ; Wildfire A; Mandalia S; Mayer H; Goodrich J; Whitcomb J; Gazzard BG
    J Infect Dis; 2005 Mar; 191(6):866-72. PubMed ID: 15717260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years.
    Briz V; Poveda E; del Mar González M; Martín-Carbonero L; González-González R; Soriano V
    J Antimicrob Chemother; 2008 Feb; 61(2):405-10. PubMed ID: 18063598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.
    Kiwanuka N; Laeyendecker O; Robb M; Kigozi G; Arroyo M; McCutchan F; Eller LA; Eller M; Makumbi F; Birx D; Wabwire-Mangen F; Serwadda D; Sewankambo NK; Quinn TC; Wawer M; Gray R
    J Infect Dis; 2008 Mar; 197(5):707-13. PubMed ID: 18266607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
    Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
    AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.
    Karlsson I; Antonsson L; Shi Y; Karlsson A; Albert J; Leitner T; Olde B; Owman C; Fenyö EM
    AIDS; 2003 Dec; 17(18):2561-9. PubMed ID: 14685050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline HIV type 1 coreceptor tropism predicts disease progression.
    Daar ES; Kesler KL; Petropoulos CJ; Huang W; Bates M; Lail AE; Coakley EP; Gomperts ED; Donfield SM;
    Clin Infect Dis; 2007 Sep; 45(5):643-9. PubMed ID: 17683002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
    Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.